Welcome back to my second episode covering several snippets of breaking news on psychiatric medications. In these episodes I don't deep dive like normal, but instead cover several important breaking news items that affect psychopharmacology and give my quick take on the news. Some of this will be trial results, FDA updates, interesting papers that were recently published, and anything else I can come up with. I have a ton of updates since the last episode. So much that I had to break it up into two episodes. The next one will be out next week. Today I'm going to talk about new approvals of old medications from new ketamines, KETARx and Nrx100, to Tonmya(r) (cyclobenzaprine) for fibromyalgia. Then, I'll also talk about some combination products containing atomoxetine (Strattera(r)) for obstructive sleep apnea. Lastly, I'll then go into a couple medications with new Phase II trial data for depression. First is a unique vasopressin 1b antagonist and the second is a selective orexin receptor antagonist. I do a bit more discussion on these topics than in the previous update episode because honestly I'm not happy about a lot of this and I want to use these new approvals to talk about the deeper issue of how these drug companies manipulate to make money. Please have a listen!
View all episodes
